Antibiotic—Lysobacter enzymogenes proteases combination as a novel virulence attenuating therapy

Ghadeer A. R. Y. Suaifan; Diana M. A. Abdel Rahman; Ala’ M. Abu-Odeh; Fahid Abu Jbara; Mayadah B. Shehadeh; Rula M. Darwish

doi:10.1371/journal.pone.0282705

Peer Review History

Original SubmissionOctober 9, 2022
9 Oct 2022 Author Response Attachments Attachment Submitted filename: Suaifan et al. response to reviewers.docx https://doi.org/10.1371/journal.pone.0282705.r001
1 Dec 2022 Decision Letter - Brahma Nand Singh, Editor PONE-D-22-27664Antibiotic – Lysobacter enzymogenes proteases combination as a novel virulence attenuating therapyPLOS ONE Dear Dr. Suaifan, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jan 05 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Brahma Nand Singh Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section. 3. Thank you for stating the following in the Acknowledgments Section of your manuscript: "The authors (GS and MS) would like to acknowledge the Deanship of the Scientific Research at The University of Jordan (2073, 2460) and Hamdi Mango Center for Scientist Research (2017) for financial support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript" Please include your amended statements within your cover letter; we will change the online submission form on your behalf. 4. Please include a copy of Table 2 which you refer to in your text on Response to Reviewers file. 5. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. Additional Editor Comments (if provided): The submitted MS has been revised accordingly. However, I have gone through the MS and found that some important earlies reports have not cited in the introduction and discussion sections of the paper. Therefore, Authors may cite the following references RSC Adv., 2021, 11, 36459-36482; Microbial Pathogenesis (2022), 170, 105678; Bioorganic & Medicinal Chemistry Letters 27(18), 2017, 4221-4228; Trends in Biotechnology (2022); 40, 1004-1017; ACS Applied Nano Materials (2021); 4(2), 1512–1528; Scientific Reports, (2019); 9 6520; RSC Advances (2015), 5 (87), 71060-71070. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. https://doi.org/10.1371/journal.pone.0282705.r002
Revision 1
29 Dec 2022 Author Response Dear Editor, Thanks for your letter sent on Dec 1th, 2022 regarding our manuscript Ref. No.: PONE-D-22-27664, entitled: " Antibiotic – Lysobacter enzymogenes proteases combination as a novel virulence attenuating therapy". Please consider our revised manuscript entitled: which has been amended based on reviewer comments to meet PLOS ONE criteria for publication. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf Response: Thanks for the comment. We can ensure that revised version meets with PLOS ONE's style requirements. 2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section. Response: Thanks for the comment. Funding Information and Financial disclosure sections in the current resubmission has been checked. 3. Thank you for stating the following in the Acknowledgments Section of your manuscript: "The authors (GS and MS) would like to acknowledge the Deanship of the Scientific Research at The University of Jordan (2073, 2460) and Hamdi Mango Center for Scientist Research (2017) for financial support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript" Please include your amended statements within your cover letter; we will change the online submission form on your behalf. Response: 1) Funding-related text has been removed from the Acknowledgment section in the revised version. 2) Funding Statement " This research was supported by a grant (2073, 2460) from the Deanship of the Scientific Research at The University of Jordan and grant (2017) from Hamdi Mango Center for Scientist Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. " 4. Please include a copy of Table 2 which you refer to in your text on Response to Reviewers file. Response: Apology as the article contains only table 1. There is no Table 2. 5. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. Response: Thanks for the comment. References were revised. 1) Reference number 7 in the submitted manuscript (Thesis) has been substituted by another article (Xu S, Zhang Z, Xie X, Shi Y, Chai A, Fan T, et al. Comparative genomics provides insights into the potential biocontrol mechanism of two Lysobacter enzymogenes strains with distinct antagonistic activities. Front Microbiol. 2022;13:966986.) 2) New references were added (Highlighted in red in the revised manuscript) to support the use of adjuvant therapy as a tool to unlock bacterial resistance. Additional Editor Comments (if provided): The submitted MS has been revised accordingly. However, I have gone through the MS and found that some important earlies reports have not cited in the introduction and discussion sections of the paper. Therefore, Authors may cite the following references RSC Adv., 2021, 11, 36459-36482; Microbial Pathogenesis (2022), 170, 105678; Bioorganic & Medicinal Chemistry Letters 27(18), 2017, 4221-4228; Trends in Biotechnology (2022); 40, 1004-1017; ACS Applied Nano Materials (2021); 4(2), 1512–1528; Scientific Reports, (2019); 9 6520; RSC Advances (2015), 5 (87), 71060-71070. Response: Thanks for the editor comments. References below were added to the revised version (Disscussion section) to highlight the increased interest in adjuvants therapy to unlock bacterial resistance by different application involving natural substances and nanotechnology. (51. González-Bello C. Antibiotic adjuvants – A strategy to unlock bacterial resistance to antibiotics. Bioorganic & Medicinal Chemistry Letters. 2017;27(18):4221-8. 52. Prateeksha P, Bajpai R, Rao CV, Upreti DK, Barik SK, Singh BN. Chrysophanol-Functionalized Silver Nanoparticles for Anti-Adhesive and Anti-Biofouling Coatings to Prevent Urinary Catheter-Associated Infections. ACS Applied Nano Materials. 2021;4(2):1512-28. 53. Abd El-Aleam RH, George RF, Georgey HH, Abdel-Rahman HM. Bacterial virulence factors: a target for heterocyclic compounds to combat bacterial resistance. RSC Adv. 2021;11(58):36459-82.) Attachments Attachment Submitted filename: Response to reviewers 2.docx https://doi.org/10.1371/journal.pone.0282705.r003
20 Feb 2023 Decision Letter - Brahma Nand Singh, Editor Antibiotic – Lysobacter enzymogenes proteases combination as a novel virulence attenuating therapy PONE-D-22-27664R1 Dear Dr. Suaifan, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Brahma Nand Singh Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: https://doi.org/10.1371/journal.pone.0282705.r004
Formally Accepted
1 Mar 2023 Acceptance Letter - Brahma Nand Singh, Editor PONE-D-22-27664R1 Antibiotic – Lysobacter enzymogenes proteases combination as a novel virulence attenuating therapy Dear Dr. Suaifan: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Brahma Nand Singh Academic Editor PLOS ONE https://doi.org/10.1371/journal.pone.0282705.r005

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .